Department of Health
From 1 March 2022, eculizumab (Soliris®) will be available under the Section 100 Highly Specialised Drugs (HSD) program of the Pharmaceutical Benefits Scheme. Until now, we have subsidised Soliris® under the Life Saving Drugs Program.
This change applies to all existing patients with paroxysmal nocturnal haemoglobinuria (PNH).
If you are a patient with PNH, make an appointment to see your treating physician to transition you to the new program.
If you are a prescriber treating patients with PNH, read our fact sheet to find out how to transition your patients.
For more details about the changes to Soliris® access for PNH patients, see our fact sheets for:
/Media Release. View in full here.
